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Cellular programming and reprogramming technology (CPART) presents a novel approach for understanding
disease progression and mechanism. In addition, CPART provides an innovative opportunity for developing
diagnostic tools and novel drug candidates for therapy. In this Forum, wewill discuss obstacles and solutions
for modeling brain disease using CPART.Introduction
Cellular programming and reprogram-
ming technology (CPART) has provided
a new way to investigate human develop-
ment and disease. This technology is
particularly useful for diseases in which
the affected tissue is not available for
cell purification and in which aspects of
cell development are crucial for the
pathology. The central nervous system
(CNS) is a good example of tissue that
falls into this category. Modeling human
brain diseases using induced pluripotent
stem cells (iPSC) or induced neural cells
(iN) has remarkable potential to generate
insights into understanding disease
mechanisms and opening new avenues
for clinical intervention. Researchers
now have the opportunity to study human
disease in living, developing neural cells
that carry the disease-specific genetic
variants that are present in the patient. In
addition, CPART represents a fresh
approach for developing original diag-
nostic tools and obtaining novel drug
candidates for CNS therapy. Importantly,
candidate compounds for treating CNS
defects fail in clinical trials in over 90%
of cases due to poor targeting, lack of effi-
cacy, and unacceptable side effects (Kola
and Landis, 2004). We firmly believe that
CPART can offer a valuable additional
tool for screening and validating CNS
compounds for pharmaceutical compa-
nies in the future.
In order for CPART to be successful
and useful, our underlying and somewhat
provocative assumption is that cellular
deficiencies can be measured in vitro,
recapitulating the phenotype that is rele-
vant to human brain disease. These
cellular deficiencies can be broken down
into levels of relevance, ranging from
highly relevant recapitulations of clinical
observations to phenotypes not previ-642 Cell Stem Cell 10, June 14, 2012 ª2012ously associated with the disease and to
lack of in vitro phenotype all together.
Ideally, the modeled in vitro phenotype is
the same as the in vivo disease-causing
phenotype that allows for the study of
the mechanism and development of the
disease. A less-pertinent model would
result in an in vitro phenotype that is
similar mechanistically but is clearly not
the same as the in vivo phenotype and
likely develops differently. This less-strin-
gent level of relevance could still be used
to screen compounds for reversal of
phenotypes and could be used as a diag-
nostic tool. The least-stringent level of
relevance would involve a phenotype
that is unrelated in any known mecha-
nistic way to the in vivo human disease
but that could still potentially be used as
a tool for the diagnosis of the disease.
All these levels of relevance require the
basic assumption that in vitro modeling
is robust enough to detect a reliable
and statistically meaningful difference
between phenotypically normal and
abnormal cells derived using CPART
(Figure 1). This is particularly important
in our view because there could be
diseases in which the variability of pheno-
types will be too big to achieve reliable
statistical value. In these specific cases,
more individuals could be included
and/or more sensitive assays should be
employed.
Nonetheless, as promising as this tech-
nology is, we are still in its early days.
There are a number of roadblocks to be
considered, and eventually overcome,
before significant progress on disease
mechanisms can be made and meaning-
ful therapies can be proposed. In this
Forum, we will discuss some of the
current obstacles, beginning with reprog-
ramming a patient biopsy and moving
towardmodeling disease-relevant pheno-Elsevier Inc.types and proposing effective therapies
(Figure 2).
Methods for Generating
Reprogrammed Cells
Ever since the original procedure for
producing iPSC was described by Taka-
hashi and Yamanaka using four factors
separately in retroviruses (Takahashi and
Yamanaka, 2006), the exact genes used
and the delivery methods have been
changing. While the mechanisms by
which the reprogramming occurs remain
incompletely understood, the robustness
of the general approach is so clear that
similar (though not exact) results can be
achieved using a variety of methodolo-
gies. Interestingly, the vast majority of
literature still employs viral integrating
strategies. Random viral integration and
incomplete silencing of reprogramming
factors are likely among the major gener-
ators of variability between cell lines.
We favor the idea that nonintegrative
methods of reprogramming will be the
best way to derive new cell lines in the
future. The field will likely reach a con-
sensus on some combination of soluble
molecules and transient nonintegrating
vectors that carry a small cluster of genes.
The limitations on types of starting cells
have also evolved from the original fibro-
blast to include many other somatic
tissues of the body. One of the important
developments has been direct program-
ming of somatic biopsy cells (usually
fibroblasts) to neural cells (reviewed in
Zhou and Tripathi, 2012). The initial
reports of direct cellular programming re-
vealed the disadvantage of not generating
a renewable source of programmed cells,
but recently several labs have shown that
programming can be achieved to a prolif-
erating population of neural precursor
cells (iNPC) that can then be propagated
Figure 1. Different Possible Outcomes in DiseaseModeling using Cellular Programming and
Reprogramming Technology
Different possible outcomes in disease modeling using cellular programming and reprogramming tech-
nology (CPART) and its relevance for effectively understanding disease mechanism, developing diag-
nostic tools, and finding novel therapies.
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mature neurons and glia (Zhou and Tripa-
thi, 2012). For the purpose of this review,
we will use the term ‘‘REPRO cells’’ to
represent both reprogrammed (iPSC)
and programmed (directly differentiated)
cells such as iNPC and iN.
Accessing the Fate of REPRO Cells
While the choice of donor cells and the
method for generating the REPRO cells
are critical considerations, another chal-
lenge is their differentiation into homoge-
neous populations of the cell type impli-
cated in the disease phenotype. This is
a rich field, and there is a steady flow of
protocols for generating specific cell
types, but much more work is required.
Most strategies for cell fate specification
are based on the achievements of in vivo
developmental neurobiologists in the last
50 years. While the molecular pathways
for generating specific cell types in the
mouse do not always recapitulate a
human in vitro setting, many of the path-
ways involved in cell fate decisions are
conserved. Moreover, there is a surge in
the drive to differentiate human REPRO
cells to specific cell lineages, which will,
in turn, provide the foundation for new
knowledge about human neural develop-
ment. An important cautionary note is
that, with our existing technology, it is
particularly challenging to generate
mature human neurons in the dish. Most
protocols currently available produce
neurons that are comparable to cells atan immature fetal stage, although a lot of
research is now dedicated to improving
the neuronal outcome in terms of maturity
and percentage of electrophysiologically
active cells. Finally, much of the effort
in vitro has been to establish protocols
for differentiating cells into specific cell
types through soluble molecules, in-
cluding growth factors and activators or
inhibitors of specific signaling pathways.
For more complete fate determination,
we will likely need to pay more attention
to combinations of cell types and struc-
tures, including vasculature, which are
critical in vivo for fate specification and
maintenance.
Variability between Lines
As more iPSC lines are produced and
shared, it has become increasingly clear
to stem cell biologists that there is vari-
ability between cell lines that emerged
after reprogramming. Differences be-
tween clonal lines have been detected
at multiple levels, including variable
expression profile levels, X-inactivation
status on female lines, genetic instability,
and differentiation potential (discussed in
Hayden, 2011). This observed variation
could be attributed in part to the current
protocols of reprogramming that include
viral integration into the host DNA, as
well as the intense cloning involving
multiple passages of the cells that is
required to apply CPART. It remains to
be seen whether the widespread use
of nonintegrating technology—which isCell Stem Cellreadily available now—will reduce thevari-
ability of the cultures. Partial reprogram-
mingand incompleteerasureof epigenetic
markshasalsobeenproposedasasource
of variability (Hayden, 2011), though some
propose that this specific concern could
be addressed by developing more strin-
gent methodologies of selecting popula-
tions of REPRO cells that have undergone
complete reprogramming. In the literature,
few attempts have been made to imple-
mentgeneral criteria for defining hallmarks
for reprogramming and differentiation,
but, given the fast pace of discovery in
the field, more research is definitely
needed to precisely dissect and deal with
many sources of variability. An example
of the dynamic nature of the iPSC charac-
terization is the use of teratoma formation
assays as the gold standard criterion for
pluripotency validation. We support the
view that teratoma generation is primarily
qualitative, is difficult to standardize, and
has questionable value for in vitro disease
modeling (discussed inMu¨ller et al., 2010).
While broadly used as a reprogramming
hallmark,many researchers arenowques-
tioning its value, particularly in light of
reports showing that partially reprog-
rammed iPSC lines can also form
teratomas (Chan et al., 2009). Another
important—and yet not fully under-
stood—source of variability is the naturally
occurring intrinsic variability between indi-
viduals. Specifically relevant to modeling
mental illnesses will be the ability to
dissect the phenotypic variability present
in neuronal cells derived from nonaffected
individuals from the clinically relevant
differences present in neurons from
affected patients.
One obvious way of addressing vari-
ability is to increase the number of
controls and patients analyzed in combi-
nation with specific cohorts of patients
who present common clinical histories
and/or respond similarly to drugs. When
possible, the use of genetically identical
individuals (i.e., monogenetic twins) who
are concordant or discordant for a mental
disorder would also contribute to
reducing variability and generating rele-
vant disease hypotheses. In addition,
generation of disease team consortiums
would greatly facilitate CPART by
enhancing the number of individuals
analyzed (and new lines produced),
promoting exchanges of cells and meth-
odologies, and improving discussion.10, June 14, 2012 ª2012 Elsevier Inc. 643
Figure 2. Obstacles to Be Overcome before Cellular Programming and Reprogramming
Technology Can Be Widely Used for Disease Modeling
Obstacles to be overcome before CPART can be widely used for understanding the mechanisms of, and
proposing meaningful therapies for patients with, brain diseases. REPRO cells is a term used in this forum
to reference both reprogrammed and programmed (direct differentiated) cells such as induced pluripotent
stem cells (iPSC), induced neural progenitor cells (iNPC), and induced neurons (iN).
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field is statistics. Given the aforemen-
tioned variability in the field, we support
the use of multiple cell lines from each
patient and ideally multiple patients with
variable phenotypes. Careful analysis of
the variance present in the data will indi-
cate the minimal number of REPRO
patient cell lines needed to obtain a statis-
tically relevant measurement. It is likely
that the number of cell lines needed will
vary accordingly with the robustness of
the assay performed. Sources of error
with low numbers of subjects are plentiful
in the field and increase the risk of both
Type 1 and Type 2 errors. The success
of this field depends on the ability to repli-
cate findings from one laboratory to
another. One of the great advantages of
this field is that the principle reagent (the
REPRO cell) can be banked and made
available to other laboratories, meaning
that we have an ever-expanding and
-renewable source of research material
that we can use to go back and compare,
contrast, and add numbers to our anal-
ysis. Thus, while variability in methods of
CPART and differentiation may mask or
misrepresent some initial findings, the644 Cell Stem Cell 10, June 14, 2012 ª2012robust and meaningful phenotypes will
emerge and persist, and the less-robust
observations will not.
A further note of caution about vari-
ability relates to the variability that exists
between individual cells from the same
clone. This variability includes expression
differences based on variable states of
differentiation between, for example, two
related neurons next to each other in the
culture dish; other variance may be
genomic and may result from intrinsic
mechanisms of genomic mosaicism,
attributed in part to mobile elements or
driven by extrinsic factors such as the
number of passages, which increases
the risk of differential genome instability.
It is likely that this is a source of variance
that will not be resolved until more
advanced methods of genomic analysis
are available.
Modeling Brain Disease
Most successful reports involving disease
modeling for neurological diseases todate
utilize cells from patients with monoge-
netic disorders in which the genemutation
is characterized. Modeling monogenic
brain disorders advanced the field, helpedElsevier Inc.to establish the basic tools for culturing
functional human neurons, and revealed
meaningful neuronal phenotypes (Mar-
chetto et al., 2010). Importantly, mono-
genic disorder modeling presents the
opportunity to perform gain- and loss-of-
function studies to confirm that the
neuronal phenotypes observed are dis-
ease specific, as opposed to a general,
nonspecific effect.
The advantages of studying monogenic
diseases aremany; not the least important
is proving, in an isogenic nondiseased
cell, that the homologous recombination
of the diseased gene is necessary and
sufficient for recapitulating the in vitro
disease phenotype. Nonetheless, a large
percentage of brain disorders (i.e., autism
and schizophrenia) have a complex na-
ture and are likely multifactorial: a combi-
nation of mutations in several genes (as
opposed to mutations in only one
gene) and extrinsic factors (influence of
neighbor cells and environment) are
involved in the disease pathology.
Crucial for the future of modeling
complex CNS diseases will be developing
novel, more-sensitive tools and improving
methodology and analysis such that they
will consistently pick up subtle but impor-
tant differences between controls and
affected cell lines (reviewed in Marchetto
et al., 2011).
New neuronal differentiation protocols
can obtain particular subtypes of neurons
that are relevant to particular diseases
(e.g., dopaminergic neurons for Parkin-
son’s disease, hippocampal and cholin-
ergic neurons for Alzheimer’s disease,
motor neurons for amyotrophic lateral
sclerosis). In addition, improving the
protocols for evaluating neuronal connec-
tivity properties, synaptic plasticity, and
electrophysiological functional outcomes
will definitely be of great value in detecting
disease-related phenotypes. Examples of
techniques that are already available but
not yet widely employed in the field are
calcium imaging, light-activated chan-
nelrhodopsins, uncaged glutamate,
transynaptic labeling using virus, multi-
electrode arrays, single-cell expression
analysis, high-resolution live imaging for
spine motility and maturation, synaptic
protein recruitment, and axonal transport-
ing dynamic visualization.
Combining ideas and technologies
from established fields will be highly
beneficial to this nascent field. A practical
Cell Stem Cell
Forumexample is the recent incorporation of
biomaterials and bioengineering tech-
niques for improved differentiation of
iPSC cultures. New alternative methods
for better compartmentalization and isola-
tion of neuronal processes using micro-
fluidic chambers have been explored
and implemented in primary neural
cultures. Compartmentalization of neu-
rons using engineered devices would
allow comparisons of the dynamic
behavior and molecular anatomy of
control versus diseased neurons in
culture. Additionally, using engineered
tridimensional biomatrices to simulate
tissue structures may more authentically
recapitulate in vivo neuronal branching
and connectivity and potentiate a more
complete in vitro maturation.
For many complex CNS diseases,
extrinsic factors play a crucial role in the
neuronal pathology. Injury to neurons
can be conferred by immunological
response from neighbor cells (microglia)
and/or from a decline in the health of sup-
porting glial cells (astrocytes and oligo-
dendrocytes). The incorporation of niche
cells into in vitro models could improve
our understanding of the non-cell-autono-
mous effects on diseased neurons. New
technology for the generation of homoge-
neous populations of glial cells from
iPSCs is now available (Krencik and
Zhang, 2011; Yuan et al., 2011). Another
alternative for teasing out non-cell-auton-
omous effects on more mature and inte-
grated neurons is in vivo grafting of
REPRO cells in rodent brains. Studying
the anatomy and function of transplanted
neurons over time informs studies of neu-
rodevelopmental aspects of the disease
and of cell-autonomous versus nonauton-
omous elements. Developmental hall-
marks such as neuronal pruning, dendritic
branching, spine formation, and matura-
tion could be dynamically observed as
transplanted neural progenitors differen-
tiate into neurons over time. State-of-
the-art intracranial live-imaging tech-
niques coupled with electrophysiological
studies could facilitate studies of func-
tional integration properties from neurons
in real time. Transplantation may also lead
to the generation of specific subtypes of
neurons that are difficult to producethrough in vitro differentiation protocols.
These transplantation studies ideally
recapitulate the in vivo characteristics of
human cells more authentically. Because
cells need to be implanted at an early
enough time to allow host factors to
more accurately act on the REPRO cells,
this process may lead to chimerism, so
both technical and ethical challenges
remain.
Advanced whole-genome sequencing
technology facilitates detection of new
mutations and relevant variations in
complex genetic diseases leading to
common clinical outcomes. Combining
in-depth DNA sequencing analysis with
in vitro disease-relevant neuronal phe-
notypes, high-throughput proteomics/
metabolomics data, and longitudinal
clinical studies of predefined cohorts of
patients will certainly provide a very
comprehensive volume of information
about disease features. What is clear is
that while CPART is evolving, so is
whole-genome technology; its depth and
accuracy are changing and improving so
rapidly that each new analysis is almost
outdated by the time it is published.
There are certainly opportunities avail-
able for CPART-based preclinical studies
at all stages of drug development. Drug
screening success for brain diseases
would depend on the relevance, robust-
ness, and scalability of the detected
in vitro phenotype. New initiatives for
drug screening using patient-reprog-
rammed cells are already in place, with
the idea of taking advantage of assays
developed in academia combined with
Food and Drug Administration-approved
drugs that have been repurposed.
Conclusion
As with many new marriages that bring
together leading-edge technology with
potential clinical applications, we are in
the honeymoon stage. Evidence is pour-
ing in every day through publications
and opinion pieces that reveal new
models, extraordinary results, and prom-
ising new applications. But of course
every honeymoon comes to an end, and
the staying power of this marriage will
depend on its ability to stand the test of
time and scrutiny. Many of the basicCell Stem Cellassumptions will be challenged, and
many more technical hurdles will need to
be overcome, especially the convergence
on the best andmost-reliable methods for
programming and reprogramming cells.
In addition, optimal ways to selectively
specify cell fates that accurately reflect
the in vivo behavior of cells will need to
be developed. Also challenging will be
the development of a variety of tools that
most sensitively and reliably measure
functional phenotypes that are relevant
to disease. While many aspects of this
marriage between basic and clinical
research will change and likely improve,
we predict that this hybrid research
approach will not go away but rather will
become an essential tool for basic biology
and translational medicine.
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